Investors Hype Robotics While Biotech Suffers a Deep Funding Winter
zebird0 · x · 2026-08-14
A tech investor points out that software investors are suddenly highly enthusiastic about robotics, despite knowing very little about hardware.
In stark contrast, the biotech sector remains in a deep funding winter despite the massive success of GLP-1 drugs. The author questions why the capital markets treat these two sectors so differently, given that both have similarly tough capital costs and timelines.
Related event: Software VCs Flock to Robotics Amid Biotech Funding Winter(2 posts)→
More from Venture
- Investors Call for Experienced Founders: Deep Expertise Offers Unprecedented Leverage in the AI Era — heyneighbor · 2026-08-14
- Swarms API Pricing Unveiled: Free Tier, Pro at $19.99/mo, Ultra at $100/mo — KyeGomezB · 2026-08-14
- CoreWeave Defends GPU Lifespan: A100 Contracts Run Through 2029 — johncoogan · 2026-08-14
- Indie Dev Reality: 3 out of 10 Projects Profit, but Compounding Lies in Code — sven_ai · 2026-08-14
- Magma: Monetizing AI Agent Interaction Logs for Developers — ycombinator · 2026-08-14
- Booming AI Market Inflates Valuations: Thrive Capital Seeks Minority Stake Sale — nmasc_ · 2026-08-14